Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant COVID-19 Vaccine (Sf9 Cells) in Healthy Adults
NCT04718467Phase 2Withdrawn
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- Feb 2021
- Primary completion
- May 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Planned start Feb 2021; status: withdrawn.
02
Drugs
recombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04718467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718467.